SRC and breast cancer: Using network pharmacology-based analysis in combination with molecular docking method, 18 protein targets, ErbB4, EGFR, CDK2, CDK6, p38 MAPK, ERK2, Lck, Src, IGF1R, PI3Kγ, VEGFR2, aromatase, PTP1B, SHP2, caspase-3, PARP-1, HSP90α and HSC70, were identified and by binding with these targets, LF triterpenoids could inhibit ErbB signaling pathway, MAPK signaling pathway, PI3K/Akt signaling pathway and VEGF signaling pathway, then inhibit breast cancer cells proliferation, and induce the cell cycle arrest and apoptosis.